We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
In the last reported quarter, the company’s earnings per share (EPS) of $4.02 surpassed the Zacks Consensus Estimate by 0.3%. Over the trailing four quarters, its earnings beat the Zacks Consensus Estimate on three occasions and missed once, delivering an earnings surprise of 0.1%, on average.
Let’s check out the factors that have shaped DVA’s performance prior to this announcement.
Factors Likely to Shape DaVita’s Q3 Results
DaVita’s third-quarter 2026 performance is likely to have benefited from improving treatment volumes and a favorable calendar comparison. Management expects full-year treatment growth near the upper end of its previous 25-50 basis-point guidance range, supported by better-than-expected patient mortality trends and improving operating performance. The third quarter has a favorable year-over-year calendar effect, which is expected to support reported treatment growth. However, a weaker commercial payor mix could continue to constrain revenue growth and profitability.
Revenue per treatment (RPT) is likely to have remained under pressure. Although higher reimbursement rates should have provided support, the expiration of Affordable Care Act subsidies and lower phosphate binder revenues are expected to have weighed on the commercial payor mix and overall reimbursement. Management expects full-year RPT growth of 1-2%, implying a bit of negative growth in the second half of 2026 compared with the prior-year period.
Cost management is expected to have improved in the quarter. Patient care costs per treatment declined sequentially in the second quarter, supported by labor productivity, operating leverage and lower phosphate binder costs. These benefits could have continued into the third quarter, although higher employee benefit expenses and other medical costs remain potential headwinds. General and administrative expenses are also likely to have reflected investments in technology and operational capabilities. Management expects full-year total cost per treatment growth of 1.25-2.25%.
DaVita reported adjusted operating income of $40 million in the second quarter for Integrated kidney care (IKC) compared with an adjusted operating loss of $19 million in the first quarter. Growth was primarily driven by the timing of revenue recognition. IKC is expected to remain the biggest driver of the anticipated $50-$100 million sequential increase in adjusted operating income from the third to the fourth quarter. This suggests that revenue timing could have limited IKC's contribution to third-quarter results, despite continued progress in managing care costs and expanding the business.
DaVita maintained its 2026 guidance for adjusted operating income of $2.15-$2.25 billion and adjusted EPS of $14.10-$15.20 following its second-quarter results. Investors will watch whether treatment growth and cost discipline can offset reimbursement headwinds and support the company’s full-year targets.
DVA’s Estimate Picture
For third-quarter 2026, the Zacks Consensus Estimate for revenues is pegged at $3.53 billion, implying an improvement of 3.2% from the prior-year quarter’s reported figure.
The consensus estimate for EPS is pegged at $3.78, indicating an uptick of 50.6% from the prior-year period’s reported number.
What Our Model Suggests About DaVita
Per our proven model, a stock with a Zacks Rank #1 (Strong Buy), 2 (Buy), or 3 (Hold), along with a positive Earnings ESP, has higher chances of beating estimates. However, this is not the case here, as you can see below.
DaVita’s Earnings ESP: DVA has an Earnings ESP of 0.00%. You can uncover the best stocks to buy or sell before they are reported with our Earnings ESP Filter.
Year to date, DaVita’s shares have surged 62%, outperforming the Medical - Outpatient and Home Healthcare industry’s 24.4% rise, the Zacks Medical sector’s 4.9% gain and the S&P 500’s 10.6% growth.
Image Source: Zacks Investment Research
DaVita’s peers like Aveanna Healthcare Holdings Inc. (AVAH - Free Report) , Quest Diagnostics (DGX - Free Report) and Encompass Health (EHC - Free Report) have underperformed it. AVAH, DGX and EHC’s shares have gained 61.3%, 40% and 16.9%, respectively, in the year-to-date period.
View the Zacks #1 Rank List
Image: Bigstock
Will DaVita's Q3 Earnings Reflect Improving Treatment Growth Trends?
Key Takeaways
DaVita Inc. (DVA - Free Report) is scheduled to report third-quarter 2026 results on Oct. 29, after the closing bell.
In the last reported quarter, the company’s earnings per share (EPS) of $4.02 surpassed the Zacks Consensus Estimate by 0.3%. Over the trailing four quarters, its earnings beat the Zacks Consensus Estimate on three occasions and missed once, delivering an earnings surprise of 0.1%, on average.
Let’s check out the factors that have shaped DVA’s performance prior to this announcement.
Factors Likely to Shape DaVita’s Q3 Results
DaVita’s third-quarter 2026 performance is likely to have benefited from improving treatment volumes and a favorable calendar comparison. Management expects full-year treatment growth near the upper end of its previous 25-50 basis-point guidance range, supported by better-than-expected patient mortality trends and improving operating performance. The third quarter has a favorable year-over-year calendar effect, which is expected to support reported treatment growth. However, a weaker commercial payor mix could continue to constrain revenue growth and profitability.
Revenue per treatment (RPT) is likely to have remained under pressure. Although higher reimbursement rates should have provided support, the expiration of Affordable Care Act subsidies and lower phosphate binder revenues are expected to have weighed on the commercial payor mix and overall reimbursement. Management expects full-year RPT growth of 1-2%, implying a bit of negative growth in the second half of 2026 compared with the prior-year period.
Cost management is expected to have improved in the quarter. Patient care costs per treatment declined sequentially in the second quarter, supported by labor productivity, operating leverage and lower phosphate binder costs. These benefits could have continued into the third quarter, although higher employee benefit expenses and other medical costs remain potential headwinds. General and administrative expenses are also likely to have reflected investments in technology and operational capabilities. Management expects full-year total cost per treatment growth of 1.25-2.25%.
DaVita reported adjusted operating income of $40 million in the second quarter for Integrated kidney care (IKC) compared with an adjusted operating loss of $19 million in the first quarter. Growth was primarily driven by the timing of revenue recognition. IKC is expected to remain the biggest driver of the anticipated $50-$100 million sequential increase in adjusted operating income from the third to the fourth quarter. This suggests that revenue timing could have limited IKC's contribution to third-quarter results, despite continued progress in managing care costs and expanding the business.
DaVita maintained its 2026 guidance for adjusted operating income of $2.15-$2.25 billion and adjusted EPS of $14.10-$15.20 following its second-quarter results. Investors will watch whether treatment growth and cost discipline can offset reimbursement headwinds and support the company’s full-year targets.
DVA’s Estimate Picture
For third-quarter 2026, the Zacks Consensus Estimate for revenues is pegged at $3.53 billion, implying an improvement of 3.2% from the prior-year quarter’s reported figure.
The consensus estimate for EPS is pegged at $3.78, indicating an uptick of 50.6% from the prior-year period’s reported number.
What Our Model Suggests About DaVita
Per our proven model, a stock with a Zacks Rank #1 (Strong Buy), 2 (Buy), or 3 (Hold), along with a positive Earnings ESP, has higher chances of beating estimates. However, this is not the case here, as you can see below.
DaVita’s Earnings ESP: DVA has an Earnings ESP of 0.00%. You can uncover the best stocks to buy or sell before they are reported with our Earnings ESP Filter.
Zacks Rank of DVA:The company currently carries a Zacks Rank #3. You can see the complete list of today’s Zacks #1 Rank stocks here.
DaVita Inc. Price and EPS Surprise
DaVita Inc. price-eps-surprise | DaVita Inc. Quote
DVA’s Share Price Performance
Year to date, DaVita’s shares have surged 62%, outperforming the Medical - Outpatient and Home Healthcare industry’s 24.4% rise, the Zacks Medical sector’s 4.9% gain and the S&P 500’s 10.6% growth.
Image Source: Zacks Investment Research
DaVita’s peers like Aveanna Healthcare Holdings Inc. (AVAH - Free Report) , Quest Diagnostics (DGX - Free Report) and Encompass Health (EHC - Free Report) have underperformed it. AVAH, DGX and EHC’s shares have gained 61.3%, 40% and 16.9%, respectively, in the year-to-date period.